Could Antibodies Be Causing Long COVID? - The "Abzyme" Story - Dr Gill
in addition to the debilitating symptoms which some patients with long Covid can experience, there is also the existential issue, whereby patients understand how little we truly know about this condition, and thus how well we are able to target the underlying problems.
Perhaps by comparison to other conditions, then it is not surprising that in the world of long Covid they are recurrent steady precious to bring about these changes, and help us understand what may be going on. On the 22nd of July 2025 the university of Virginia release a paper discussing how their scientist had managed to identify rogue antibodies, which they dubbed abzymes, as a potential cause of some long Covid symptoms
Hello and welcome back to the channel. My name's Dr James Gill and you've joined me for an update
on COVID-19 slash long COVID. There's recently been a discovery from the University of Virginia
which might be a game changer when it comes to targeting long COVID. Now it has been assumed
that a subset of long COVID patients with fatigue as their base symptom may be suffering due to
antibodies that are present and crucially remain in the blood after an infection of COVID-19.
An article in Nature in 2024 highlighted that antibodies raised following a COVID-19 infection
may be part of the pathology of long COVID after experiments whereby antibodies isolated from
patients with long COVID were transferred into mice and those mice appeared to demonstrate
both an increased pain sensitivity and a reduction in movement. Now this study is
particularly important because when trying to establish a pathological process we need to
determine whether an unobserved interaction between two things is merely coincidental
or is actually due to a causal relationship. Now this is particularly important as in the
early stages of COVID and the long COVID story all approaches to treating patients were based on
correlations without necessarily being supported by causality which led to some odd medications
being thrown around. Now it's important to highlight that's not a pure criticism. I mean
when you're dealing with an entirely new disease it takes time for science to be able to demonstrate
that cause and effect are truly linked and things are catching up finally it seems. Now at this
point it's fair to state that for some patients there is a cause and effect relationship between
the generation of auto-antibodies. Antibodies that are directed at the patient's own body
as a result of the COVID infection and the development of long COVID symptomology
might come from that in those patients. The twist here is that the researchers at the University
of Virginia have now put forward a paper suggesting why those auto-antibodies cause
symptoms because they might act like enzymes in a new term described as abzymes. Now when I say this
is hot off the press research I literally mean that. This paper was published in the 22nd of July
2025 so this is brand new. So taking that this is brand new information if we go backwards to the
nature of a COVID-19 infection most people are aware that the COVID-19 virus enters the cell
via its spike protein binding to the ACE2 and in doing so the spike protein then blocks the ACE2
from functioning as it should do. Now for clarification here the ACE2 is an enzyme and
doesn't function as a receptor however certain viruses like COVID-19 use ACE2 as an entry point
into the cell and thus often described as being the ACE2 receptor in COVID conversations. Now
that's a crucial reframing that we need to establish before we go any further. So why
does this matter? Because as the naming of ACE2 indicates there's two main ACE enzymes in the body
and I think it's worth more to highlight at this point that ACE stands for angiotensin converting
enzyme. So to make things straightforward the ACE enzyme converts angiotensin 1 to angiotensin 2
and in turn that leads to a rise in blood pressure, promotes fibrosis, inflammation,
none of these being very positive. Now a side note this is why we use ACE inhibitors to treat
blood pressure because we're stopping that occurring. ACE2 on the other hand is a much
nicer enzyme it works in the opposite way it converts angiotensin 2 to angiotensin 1. Why
does this matter? Because reducing angiotensin 2 to angiotensin 1 has the effect of reducing blood
pressure, reducing inflammation and reducing fibrosis. Basically ACE2 activity counterbalances
the activity of ACE. So if we go back to the fact that COVID-19 enters the cell via the ACE2 enzyme
that enzymatic capacity is massively degraded. Essentially you're getting a virus shoving itself
through a protein making a port out of it. In doing so this leads to increased angiotensin 2
levels and increased levels of inflammation because you've kind of damaged that protective
ACE2 enzyme by shoving a virus through it. Now this isn't new information and it doesn't relate
to antibodies either. So how does ACE2 relate to the University of Virginia's findings about
antibodies? When the body detects an infection it can raise antibodies to the antigens on the
infectivations. In the case of COVID-19 the main antigen there is the virus spike protein. So given
the spike protein binds to ACE2, i.e. the spike is a mirror image of ACE2, the antibodies directed
towards the spike protein would look similar to ACE2 themselves. So the UVA team have suggested
that these antibodies can be so similar to ACE that they then act like copies of the ACE. Little
enzymes now no longer bound to the cell but floating around the body. For clarification the
researchers confirm there is no relationship with these abnormal antibodies or abzymes and
vaccination, suggesting it's something to do with the COVID-19 infection itself being a causative
factor. Thus we return to the concept of cause and effect. The UVA team did the most sensible thing
they could. They took these suspected rogue antibodies from patients with long COVID and then
tested the activity level of ACE2 in that blood. Then when those antibodies were removed from the
blood that observed activity from ACE2 disappeared. Crucially when these antibodies were removed from
the blood the observed enzymatic activity from ACE2 disappeared, i.e. we've been able to prove
a causal correlation rather than just random chance. This discovery may explain why some
long COVID patients experience issues with their blood pressure and have subsequent problems with
fatigue. But more than just providing another bit of interest in the long COVID story this might go
some way to explaining why some patients have benefited from a treatment called plasma apheresis.
This is essentially removing proteins and antibodies from the blood.
However what about the studies such as a recent article in Nature suggesting that plasma aphoresis
has no effect? Things we've had previous case studies suggested aphoresis might give a benefit
but this well might be due to patient selection. So the recent paper from Nature was a
very well controlled trial. It was a randomized controlled trial and that's one of the gold
standard approaches for evaluating cause and effect and here it showed no clear benefit.
It might be that the work from UVA which was acknowledged to target a narrow band of long
COVID sufferers might be able to be repurposed as a testing strategy to identify which patients
might have a clinical benefit from aphoresis. And that's the crucial thing here at each step
of the way we're finding new things about COVID and long COVID that's allowing us to review
previous information such as some people saying aphoresis works and big studies saying it doesn't
suggesting that maybe it does work for some people and we need to find a way to identify those people
and it's possible this has done that. So I know that a lot of people affected by long COVID get
quite demoralized about the lack of movement of the science but I think this is a crucial bit to
a getting a better test and b getting ways that we can manage patients. I hope this has been a useful
video. If you'd like to put any questions in the comments we'll see how we can come back to them
and yeah take care and we'll see in the next one. Cheerio!